Table 7.
Studies of stereotactic body radiotherapy for stage I NSCLC in the elderly
| Author | Age (range) | n | T stage | Doses | Local control | Overall survival |
|---|---|---|---|---|---|---|
| Haasbeek CJ et al. [9] |
≥ 75 (75–91) |
193 |
T1 118 |
60 Gy/3 fr |
89% at 3 years |
45% at 3 years |
| |
|
|
T2 85 |
60 Gy/5 fr |
|
|
| |
|
|
|
60 Gy/8 fr |
|
|
| Takeda A et al. [12] |
≥ 80 (80–91) |
109 |
T1a 32 |
50 Gy/4 fr |
82.3% at 3 years |
53.7% at 3 years |
| |
|
|
T1b 35 |
40 Gy/ 5 fr |
|
|
| |
|
|
T2 42 |
|
|
|
| Sandhu AP et al. [11] |
≥ 80 (80–89) |
24 |
T1 18 |
48 Gy/4 fr |
100% |
74% at 2 years |
| |
|
|
T2a 6 |
56 Gy/5 fr |
(4.3–61.2 months) |
|
| This study |
≥ 85 (85–93) |
20 |
T1a 9 |
48 Gy/4 fr |
83.1% at 3 years |
71.2% at 2 years |
| (Hayashi S et al.) |
|
|
T1b 7 |
60 Gy/10 fr |
|
40.7% at 3 years |
| T2a 4 |